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Autism Spectrum Disorder (ASD) is a common neurodevelopmental disorder with
a strong but complex genetic component. Recent family based exome-sequencing
strategies have identified recurrent de novomutations at specific genes, providing strong
evidence for ASD risk, but also highlighting the extreme genetic heterogeneity of the
disorder. However, disruptions in these genes converge on key molecular pathways early
in development. In particular, functional enrichment analyses have found that there is a
bias toward genes involved in transcriptional regulation, such as chromatin modifiers.
Here we review recent genetic, animal model, co-expression network, and functional
genomics studies relating to the high confidence ASD risk gene, CHD8. CHD8, a
chromatin remodeling factor, may serve as a “master regulator” of a common ASD
etiology. Individuals with a CHD8 mutation show an ASD subtype that includes similar
physical characteristics, such as macrocephaly and prolonged GI problems including
recurrent constipation. Similarly, animal models of CHD8 disruption exhibit enlarged
head circumference and reduced gut motility phenotypes. Systems biology approaches
suggest CHD8 and other candidate ASD risk genes are enriched during mid-fetal
development, which may represent a critical time window in ASD etiology. Transcription
and CHD8 binding site profiles from cell and primary tissue models of early development
indicate that CHD8 may also positively regulate other candidate ASD risk genes through
both direct and indirect means. However, continued study is needed to elucidate the
mechanism of regulation as well as identify which CHD8 targets are most relevant to
ASD risk. Overall, these initial studies suggest the potential for common ASD etiologies
and the development of personalized treatments in the future.
Keywords: autism, autism spectrum disorder (ASD), CHD8, systems biology, co-expression networks, functional
genomics, subtype, de novo mutations
INTRODUCTION
Autism spectrum disorder (ASD) is a lifelong neurodevelopmental disorder characterized by
restricted, repetitive behaviors and impaired communication and social interactions (American
Psychaitric Association, 2013). ASD can have a considerable impact on quality of life as many
people with ASD experience difficulties communicating, developing relationships, and managing
restrictive behaviors (American Psychaitric Association, 2013). Additionally, the prevalence of
ASD appears to have steadily increased over the last few decades, from <0.5% of American
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school aged children in the 1970s to 2% in 2012 (Blumberg
et al., 2013). The most recent estimates for the median worldwide
prevalence of autism and pervasive developmental disorders is
about 1 in 160 children (Elsabbagh et al., 2012) and 1 in 68
children in the US (Centers for Disease Control, 2014). The
apparent rise in ASD has prompted a great deal of interest and
research into identifying the underlying causes of the disorder.
Many studies have indicated a strong genetic contribution for
ASD risk (Geschwind and State, 2015). Early twin and familial
studies demonstrated compelling evidence for the heritability
of ASD due to the high rate of concordance for ASD between
monozygotic twins (0.62–0.94) as opposed to dizygotic twins
(0.05–0.62) and increased relative recurrence risk for siblings
of affected individuals (10.1%; Abrahams and Geschwind, 2008;
Risch et al., 2014; Colvert et al., 2015). However, the overall ASD
genetic architecture is complex with (1) risk being conferred
by many independent genomic loci and contributions from
common and rare variants, as well as new or de novo mutations,
(2) factors that range in size, from single base changes to large
chromosomal deletions/duplications or other rearrangements,
(3) impacts that include necessary and sufficient single variants,
to small (oligogenic) and large (polygenic) sets of factors, (4)
the relative contributions of these factors are likely different in
subpopulations, such as simplex (single sporadic presentation
in an individual, with no previous family history) vs. multiplex
(multiple affected individuals in a family), or other demographics
yet to be elucidated. These realities have hampered traditional
gene discovery methods.
Despite these challenges, recent advances in sequencing
technology and novel approaches have begun to unlock the
genetics of idiopathic ASD and high confidence risk genes are
beginning to emerge that shed new light on the underlying
biology of this disorder. Here, we highlight one such gene,
Chromodomain helicase binding protein 8 (CHD8). We review the
discovery of CHD8 as one of the most mutated genes in simplex
ASD, its molecular function, associated ASD subtype, and its
potential role as a master regulator of other candidate ASD risk
genes. Although CHD8 is still just one of many ASD risk genes,
these data point toward at least one converging neuromolecular
mechanism in ASD etiology and the potential stratification of
ASD into distinct genetic/biologic subtypes. This promises to
have major implications for the future as we strive to develop
personalized therapies and precision treatments for individuals
with ASD.
GENOMIC DISCOVERY REVOLUTION
Earlier comparative genomic hybridization and genotyping
array studies advanced the genomewide discovery of large
regions of chromosomal deletions or duplications, termed copy
number variants (CNVs), as substantial contributors to the
risk of developing neurodevelopmental disorders (Rosenfeld
et al., 2010). CNVs typically involve gains or losses of many
genes and can show diversity in penetrance and expressivity.
While these CNVs play a critical role in the architecture of
neurodevelopmental disorders, with few expectations, it has
been difficult to get at the underlying locus or loci that are
responsible for this risk. The advent of whole-exome (the entire
protein coding exons of the genome) sequencing allowed for
mutation detection at single-base resolution and was initially
applied to Mendelian disorders (Ng et al., 2010). A number
of groups began applying these methods to small cohorts of
sporadic cases of a variety of conditions, including idiopathic
intellectual disability (ID), ASD, and schizophrenia, focusing
on parent-child trios or families (Vissers et al., 2010; Girard
et al., 2011; O’Roak et al., 2011; Xu et al., 2011). It was
hypothesized that such families would likely be enriched for
de novo mutations related to the condition, thereby allowing
the identification of novel genetic events with major biologic
effect in an unbiased genomwide fashion. These initial studies
demonstrated the feasibility of obtaining exome data of sufficient
quality across the trios (>90% jointly covered) and filtering
strategies to identify the ∼1 true de novo event expected
per generation (Veltman and Brunner, 2012). Moreover, they
appeared to yield a large number of possible candidate genes for
these conditions.
For simplex or sporadic ASD, these efforts were greatly
expanded in 2012 with four groups publishing the results
of hundreds of families independently (Iossifov et al., 2012;
Neale et al., 2012; O’Roak et al., 2012b; Sanders et al., 2012).
Mutations occurred in genes with very diverse functions and
in >900 ASD probands (affected individuals) only six genes
exhibited recurrent likely loss-of-function (LoF) mutations,
defined as nonsense (premature stop codon resulting in gene
truncation), canonical splice-site (altered donor or acceptor
splice sites leading to improperly splicedmRNA) or frameshifting
nucleotide insertion/deletion (indel), suggesting extreme locus
heterogeneity. One of the genes identified with two LoF
mutations in 209 ASD affected children from the Simons Simplex
Collection (SSC) by O’Roak and colleagues was CHD8, an
ATP-dependent chromatin-remodeling factor (O’Roak et al.,
2012b; Table 1). CHD8 protein was also part of a large protein-
protein interaction network emerging from the LoF and most
severe missense mutations. This network was ranked highly
for similarity to previously identified ASD risk genes using
a network walking approach. Furthermore, the locus specific
mutation rate for CHD8 suggests that it was highly unlikely
to find two independent mutations at random (in the single
study), providing additional evidence for CHD8 as an ASD risk
factor (O’Roak et al., 2012b). Mutation of CHD8 had not been
previously implicated with ASD, except in one concurrent study
examining balanced chromosomal abnormalities in ASD and
other neurodevelopmental disorders (Talkowski et al., 2012).
Talkowski and colleagues mapped a balanced translocation
involving 3q25.31 and 14q11.1 [46 XX, t(3;14) (q25.31;q11.2)dn],
which directly disrupted only one gene, CHD8 at the 14q11.1
breakpoint. The proband was diagnosed with ASD, ID, and had
dysmorphic facial features. Large de novo deletions of 14q11.2
were previously observed in three other subjects that all exhibited
developmental delay (DD) and cognitive impairment and similar
dysmorphic features including widely spaced eyes, short nose
with broad nasal tip, and unusual helical root formation of
the ear (Zahir et al., 2007). The presence or absence of ASD
was not noted. The overlapping regions lost in these three
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TABLE 1 | De Novo CHD8 Mutations.
Chr 14
Position
Refa
Allele
Alta Allele Mutation Location
(HGVS)b
Mutationc
Type
Diagnosisd VIQe NVIQf FSIQg Database
/Cohorth
Author, Year
2,189,9618 G C p.Ser62X Ns ASD 75 78 74 SSC O’Roak et al., 2012a
21,899,168 C T p.Arg212Gln Ms ASD 72 TASC O’Roak et al., 2014
21,895,989 del(47)† A c.1593_1601+38del† Ssv ASD SSC Iossifov et al., 2014
21,882,516 G T p.Gln696Lys Ms ASD 88 125 TASC O’Roak et al., 2014
21,878,133 G GT p.Tyr747X Fs ASD 25 38 32 SSC O’Roak et al., 2012a
21,876,700 A G p.Leu834Pro Ms ASD ASC De Rubeis et al., 2014
21,876,489 C T p.Met904Ile Ms ASD/ID 63 TASC O’Roak et al., 2014
21,871,373 T C c.3519-2A>G Sp ASD 37 47 43 SSC O’Roak et al., 2012a
21,871,790 C A p.Glu1114X Ns ASD 27 41 34 APP Bernier et al., 2014
21,871,178 G A p.Gln1238X Ns ASD 20 34 27 SSC O’Roak et al., 2012b
21,870,652 C T p.Arg1242Gln Ms ASD ASC De Rubeis et al., 2014
21,870,169 G A p.Arg1337X Ns ASD 85 86 84 SSC O’Roak et al., 2012a
21,868,219 G A p.Arg1580Trp Ms ASD 97 74 TASC O’Roak et al., 2014
21,867,866 T G p.Tyr1642LeufsX25 Ssv-Fs ASD ASC De Rubeis et al., 2014
21,867,866 T G c.4818-2A>C Ssv ASD 93 TASC O’Roak et al., 2014
21,865,980 A T p.Ser1606ArgfsX8 Ssv-Fs ASD ASC De Rubeis et al., 2014
21,865,980 A T c.5051+ 2T>A Ssv ASD 96 103 TASC O’Roak et al., 2014
21,862,642 C T p.Gly1602ValfsX15 Ssv-Fs ASD ASC De Rubeis et al., 2014
21,862,535 G A p.Arg1834X Ns ASD TASC O’Roak et al., 2014
21,862,159 CC C p.Glu1932SerfsX3 Fs DD/ID/ASD 46 Troina Bernier et al., 2014
21,861,643 TCTTC T p.Glu2103ArgfsX3 Fs ASD 44 67 59 SSC O’Roak et al., 2012a
21,861,376 ACT A p.Leu2120ProfsX13 Fs ASD 90 93 91 SSC O’Roak et al., 2012b
21,860,919 C A p.Ser2173X Ns ASD/SHZ Mccarthy et al., 2014
21,861,328 T TC p.Glu2136ArgfsX6 Fs ID <40 Troina Bernier et al., 2014
21,854,022 GGGT G p.His2498del Aa ASD 84 98 92 SSC O’Roak et al., 2012a
t.3;14,q25.31;q11.2 Tr ASD/ID AGRE Talkowski et al., 2012
aVCF format, hg19 coordinates.
bAccession number: NP_001164100.1; Ref Seq number: NM_001170629.1.
cFs, Frameshift; Ns, Nonsense; Tr, Translocation; Aa, Single amino acid deletion; Sp, Splice; Mns, Missense near splice site; Ms, Missense; Ssv, Splice site variant.
dASD, Autism Spectrum Disorder; ID, Intellectual Disability; SHZ, Schizophrenia.
eVIQ, Verbal I.Q.
fNVIQ, Non Verbal I.Q.
gFSIQ, Full Scale I.Q.
hSSC, Simons Simplex Collection; AGRE, Autism Research Genome Exchange; ASC, Autism Sequencing Consortium; TASC, The Autism Simplex Collection.
†
CAAGCTCAAGTGAGTACTCCTTGCTACTGTGATGGGACGT.
cases included CHD8 and SUPT16H. CHD8 was suggested as
a possible candidate gene for these abnormalities (Zahir et al.,
2007).
In an effort to identify additional mutations and firmly
implicate CHD8 and other strong candidates, targeted re-
sequencing studies utilizing cost-effective modified molecular
inversion probes (MIPs) were applied to larger cohorts of
ASD and DD probands. In the first such study, the protein
coding regions of 44 genes were successfully sequenced in
2446 ASD probands from the SSC (O’Roak et al., 2012a).
Seven additional de novo CHD8 mutations were identified:
six LoF variants and a single amino acid deletion, including
a mutation missed by exome sequencing (Table 1). This
finding was highly significant as determined by a model
of recurrent gene mutation, firmly implicating de novo LoF
mutations in CHD8 with ASD risk (p < 2 × 10−9).
Including exome data available at the time, 9/2573 (0.35%)
SSC probands carried a CHD8 mutation, making this locus
one of the most frequently mutated in sporadic/simplex
ASD.
These resequencing studies were further extended in a broader
neurodevelopmental cohort of 3730 children with ASD or DD
(Bernier et al., 2014), 898 ASD confirmed probands from The
Simplex Autism Collection (TASC; O’Roak et al., 2014), as well
as ∼2500 unaffected children from SSC or TASC. These studies
identified six additional de novo LoF variants, four de novo
missense variants, and one inherited LoF variant. LoF mutations
were not seen in unaffected siblings or in an additional 6503
general population control (Bernier et al., 2014; O’Roak et al.,
2014). In total, 16 de novo CHD8 mutations (0.46%, Poisson
95% CI: 0.26–0.75%) were identified in the SSC and TASC
cohorts, both of which required probands tomeet ASD criteria on
the Autism Diagnostic Interview-Revised (ADI-R) and Autism
Diagnostic Observation Schedule (ADOS; Lord et al., 1994,
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1999). Combined with the more broadly defined Bernier et al.
cohort, the observed de novo rate is 0.3%. These findings further
strengthen the association of de novo mutations in CHD8 with
ASD risk by identifying mutations in independent cohorts.
In late 2014, two large-scale exome sequence studies were
also published, including ∼2500 families from the SSC (Iossifov
et al., 2014) and 1478 families and 1673 case-only by the
Autism Sequencing Consortium (De Rubeis et al., 2014). In the
SSC one new additional CHD8 mutation was identified (nine
previously identified including MIP and exome data). The ASC
identified two CHD8 de novo missense mutations from the
family and three splice site variants from case only exome data
(through genotyping selected parents; De Rubeis et al., 2014).
Risk genes were identified using a statistical approach called
TADA (Transmission and De Novo Association), that integrates
family-based (de novo and transmitted) and case-control data
(He et al., 2013). In this analysis, CHD8 was also identified as one
of the top 13 ASD risk genes with a false discovery rate (FDR)
of <0.01. In summation, both exome and targeted resequening
data have firmly demonstrated that de novo CHD8mutations play
an important role in ASD risk.
CHD8 MUTATIONS DEFINE A SUBTYPE OF
ASD
CHD8 is not only one of the most recurrently mutated
genes in sporadic ASD, but also appears to give rise to
a distinct ASD phenotype. The first two probands with
CHD8 mutations identified from the early sequencing efforts
of O’Roak and colleagues, interestingly, had unusually large
head circumferences (macrocephaly; O’Roak et al., 2012b).
Similarly, the index case from Talkwoski et al. carrying the
CHD8 disrupting balanced translocation also presented with
macrocephaly and had dysmorphic facial features including
prominent forehead and eyes and posteriorly rotated ears
(Talkowski et al., 2012). Noting this, head circumference of the
the eight probands with LoF mutations in CHD8 identified from
targeted re-sequencing of the SSC (O’Roak et al., 2012a) was
examined. They found that head size was significantly larger in
the individuals with CHD8mutations (greater than two standard
deviations) as opposed to those without. Additionally, about
2% of SSC probands with macrocephay had CHD8 mutations.
Macrocephaly has been recognized in other genetic etiologies of
ASD, mainly loss of PTEN function and deletions in 16p11.2
(Butler et al., 2005; Shinawi et al., 2010).
To expand the group of individuals with known CHD8
mutations and assess the potential for a CHD8 related
subphenotype, patients identified through the exome and
targeted sequencing ASD and DD cohorts were invited to
participate in a comprehensive structured evaluation using a
battery of standard cognitive, adaptive, and language tests (n =
8; Bernier et al., 2014). Including previous clinical reports
on other subjects (n = 7), phenotypic data on 15 total
patients with disruptive CHD8 variants were included in the
evaluation (13 de novo, one inherited, and one of unknown
origin; Figure 1A and Table 2). ASD was the most common
FIGURE 1 | Phenotypic characteristics of patients with CHD8
Mutations. (A) Common facial features of patients with CHD8 mutations
include macrocephaly, hypertelorism, down-slanted palpebral fissures, broad
nose, pointed chin, and prominent supra-orbital ridge. (B) Longitudinal head
circumference data for two patients (red and blue). At 2 months after birth,
orbital frontal head growth is pronounced. Head growth continues to be in the
97th percentile throughout childhood. Figure originally published in Bernier
et al. (2014) used with permission.
TABLE 2 | Phenotypic Summary of Patients with CHD8 Mutations.
Patient characteristics Number (%)
ASD 13/15 (87%)
Tall stature 12/14 (86%)
Macrocephaly* 12/15 (80%)
GI problems* 12/15 (80%)
Sleep problems 10/15 (67%)
Intellectual disability 9/15 (60%)
*Indicates significantly different from the typical ASD population.
diagnosis with 13 of 15 meeting a strict diagnosis on both
“gold standard approaches,” ADI-R and ADOS. Macrocephaly,
defined as orbitofrontal circumference greater than two standard
deviations of age and sex matched means, was exhibited in 12 of
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15 patients (Table 2). Head circumference velocity data (n = 2)
showed an initial orbital overgrowth within the first 2 months
post birth and a continued trajectory of large head growth
at or above the 97th percentile throughout early childhood
(Figure 1B). The proportion of CHD8 mutation carriers with
macrocephaly is significantly greater than that seen in the
typical ASD population (p = 2.1 × 10−21). There were also
many similarities in facial features among the group including:
prominent forehead, wide set eyes, broad nose with full nasal
tip, and pointed chin (Figure 1A). A majority also reported
gastrointestinal (GI) problems, including recurrent constipation,
and sleep problems, particularly with falling asleep (Table 2).
Two patients described suffering from an inability to sleep
for two-three straight days. Cognitive impairment was also
pervasive, but intelligence spanned a wide range with some
in normal range. Moreover, there is indication that additional
symptoms may manifest as the children age. Three of the three
female patients (including the translocation case) experienced
precocious puberty (Talkowski et al., 2012; Bernier et al., 2014).
The implications of a CHD8 specific phenotype suggest
ASD could be stratified into different subtypes based on
genetic etiology. Identification of these subtypes would provide
insight into ASD presentation and pathology in genetically
homogenous populations and aid in the development and
evaluation of treatment approaches (Bernier et al., 2014). Other
high confidence ASD risk genes that exhibit recurrent loss of
function mutations, such as ADNP and DYRK1A also appear
to be associated with emerging subphenotypes (Helsmoortel
et al., 2014; Bronicki et al., 2015; Ji et al., 2015). CHD8 appears
to have a great deal of specificity for the ASD phenotype as
almost all individuals identified from the screen met the criteria
for ASD even though the cohort was not strictly defined for
ASD individuals. This however may often not be the case as
other strong ASD risk genes show more variable expressivity.
For example, SYNGAP1 and CHD2 have been independently
implicated in other neurological disorders such as epileptic
encephalopathies (Carvill et al., 2013). Future studies examining
how these similar genetic mutations span our current diagnostic
and clinical boundaries may provide novel insights into the
development of common neuropathologies.
A CHROMATIN MODIFIER WITH DIVERSE
FUNCTIONS
CHD8, previously called Duplin, was first identified in a
screen for novel interactors within the canonical Wnt/β-catenin
pathway using a yeast two-hybrid assay with a cDNA library
generated from rat brain (Sakamoto et al., 2000). CHD8 is a
member of the chromodomain-helicase-DNA binding protein
family. The CHD family is characterized by a SNF-2 like ATPase
and two chromo (chromatin organization modifier) domains
(Marfella and Imbalzano, 2007). The first CHD gene, CHD1,
was identified in a search for Ig promoter binding proteins
(Delmas et al., 1993; Woodage et al., 1997) At least nine other
members have been characterized to date with varying patterns
of expression in timing and localization. The CHD family is a
structurally diverse group comprised of three main subfamilies
categorized by the presence of certain functional domains
(Marfella and Imbalzano, 2007). CHD1 and CHD2 proteins
contain DNA binding domains near the C-terminus that are
thought to recognize AT richmotifs. CHD3 and CHD4 lack DNA
binding domains and instead have PHD (plant homeo domain)
Zinc finger like domains that may recognize methylated histones
and potentially have repressive functions. CHD5-CHD9 also
have DNA binding domains, along with additional functional
domains located at the C-terminus. CHD8, as well as CHD7
and CHD9, contain a BRK domain, which is often seen in
other SWI/SNF like proteins, and a DNA binding domain.
Other SWI/SNF like complexes, such as BAF, regulate neural
tube closure and neuron progenitor identity and differentiation
(Ronan et al., 2013). Based on its ATP-dependent chromatin
remodeling capabilities and SWI/SNF like domains, a potential
role for CHD8 may lie in the regulation of neuronal progenitor
cells.
Studies of CHD8 protein in the context of human cellular
function show that it is involved in the regulation of transcription
factor activity. CHD8 is able to activate the transcription of
genes driven by U6 promoters through interactions with the
transcription factor hStaf (Yuan et al., 2007). CHD8 is also
required for CTCF, a major transcriptional repressor, to function
as an inhibitor and insulator (Ishihara et al., 2006). CHD8 can
also regulate RNA synthesis as well due to interactions with
RNA polymerase II (Rodríguez-Paredes et al., 2009). CHD8 also
promotes cellular proliferation in multiple human-derived cell
types. Cells with CHD8 knockdown were found to have highly
reduced S-phase cell populations and increased populations
of cells arresting in G1 (Rodríguez-Paredes et al., 2009). This
effect was later found to be a result of CHD8 binding to S-
phase-dependent promoters and recruiting E2F, a transcription
factor which controls cell cycle regulation (Subtil-Rodríguez
et al., 2014). CHD8’s role in cell cycle regulation could be a
contributing factor in the observed macrocephaly exhibited by
individuals with CHD8 LoF mutations. While macrocephaly may
suggest overproliferation, in mouse models deficient in PTEN,
macrocephaly appears to be attributed to increased cell body
or soma size. Similarly, if cells are unable to progress through
the cell cycle due to CHD8 loss, they may continue to grow
in size (Kwon et al., 2001; Luikart et al., 2011). However, both
CHD8 upregulation and downregulation has been observed in
cancers suggesting CHD8 cell cycle regulation is likely complex
and further study will be needed to determine how it impacts
neurodevelopment (Lawrence et al., 2014; Subtil-Rodríguez et al.,
2014).
What is also still unclear is the mechanism by which
CHD8 controls transcription factor activity. Many studies
have demonstrated that CHD8 has affinity for histone H3
lysine 4 (H3K4me3), a marker for active transcription, and
is present at active promoters (Yuan et al., 2007; Rodríguez-
Paredes et al., 2009; Sugathan et al., 2014; Cotney et al.,
2015). Additionally the loss of CHD8 protein was associated
with CpG hypermethylation and histone hypoacetylation near
CTCF binding sites. Though CHD8 did not affect the ability of
CTCF to bind DNA, potentially the CTCF-CHD8 complex may
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interact with methyltransferases and histone acetyltransferases to
influence the state of nearby chromatin (Ishihara et al., 2006).
Thus, CHD8 could promote transcription factor binding by
making chromatinmore accessible or acting as a scaffold between
H3K4me3 labeled histones and the transcription factor.
CHD8 DISRUPTION IN ANIMAL MODELS
MIMICS HUMAN PHENOTYPES
In the in vivo setting, CHD8 was first examined in the context
of β-catenin signaling due to its nuclear localization and ability
to repress β-catenin dependent transcription (Sakamoto et al.,
2000). In zebrafish, β-catenin is necessary for axis formation.
Dorsal injections of Chd8 mRNA, causing overexpression of the
protein, resulted in loss of the head. CHD8 expression in the
zebrafish is enriched in the brain and spinal cord at 1 day post
fertilization, and becomes progressively restricted to head and gut
after 3–4 days post fertilization. Expression appears strongest in
the mid-gastrula stage suggesting an important role for CHD8
in embryonic development regulating Wnt/β-catenin activity
(Sakamoto et al., 2000).
The association of macrocephaly with a reduction in Chd8
expression is also observed in zebrafish. An increase in
the interorbital distance, a surrogate measurement for head
circumference, is seen in fish treated with Chd8 targeting
morpholinos (Bernier et al., 2014; Sugathan et al., 2014). The
distance increases in a morpholino dose dependent fashion.
The reduction in CHD8 also coincides with increases in
chordin, required in forebrain development, otx2, early marker
of midbrain/forebrain neural progenitor cells, and HuC/D,
marker for newborn neurons, indicating elevated proliferation,
particularly in the mid and forebrain (Bernier et al., 2014). The
zebrafish studies also suggest a role for CHD8 in GI development.
Many of the human patients with CHD8 mutations suffer from
severe GI issues. Morpholino treated zebrafish have decreased
gut motility as evidenced by delayed progression of fluorescent
microspheres (Bernier et al., 2014). There is also an overall
reduction in enteric neurons in the hindgut.
Similarly in mice, Chd8 expression is at its highest
embryonically at E8.5–E12.5 but reduced by E16.5 and low
in newborns. Therefore, function is likely restricted to early-
middle stage embryonic development (Nishiyama et al., 2004).
Expression of Chd8 is most prominent in the brain, face,
branchial arches, limb buds, and tail. Complete knockout of
Chd8 is embryonic lethal. Embryos are resorbed by E9.5 but still
recoverable by E8.5. Growth begins to delay as soon as E5.5 and is
completely arrested at E6.5 with pronounced apoptosis occurring
at E7.5. Heterozygotes though did not have gross abnormalities
and were fertile. Interestingly, Wnt/β-catenin targets are not
increased suggesting that aberrant signaling is likely not the
cause for lethality. Rather, Chd8 protein regulates p53 activity
by recruiting histone H1, forming a p53-Chd8-H1 complex that
represses p53 target gene expression (Nishiyama et al., 2009).
Unrestrained p53 activity appears to be the cause for the massive
apoptosis seen in embryos. Deletion of p53 in Chd8−/− mice
delayed arrest to E10.5 at which time embryos died from a heart
defect. Chd8−/− p53+/− mice did not recover as well. Taken
together, these studies demonstrate a conserved role for CHD8
as a regulator of early formative developmental pathways.
A CHD8-ASD DEVELOPMENTAL WINDOW
With the great functional diversity observed in the de novo, rare
variant, and other candidate ASD risk genes, it seems difficult
to reconcile their role in an overarching mechanism for ASD
biology. However, a number of biologic network approaches
suggest that there may be a converging biology at particular
developmental windows and brain regions, which includesCHD8
as a central player. These approaches are leveraging new spatial
and temporal genomics data from developing human and non-
human primates, such as the BrainSpan Atlas, a freely available
resource that includes gene expression (microarray and RNA-
seq) and in-situ hybridization data sets (Shen et al., 2012). As in
other organisms, CHD8 expression seems to be most significant
early in human development. While CHD8 is widely expressed
in the adult brain, expression is highest at 9–16 post conception
weeks (PCW) in both progenitor and post mitotic neocortical
layers and then gradually declines (Bernier et al., 2014).
To discover time points of development and brain regions
for which candidate and high-confidence ASD risk genes,
such as CHD8, may converge, two recent concurrent studies
made use of BrainSpan’s gene expression data to develop co-
expression networks or modules representing genes that share
similar expression patterns during development (Parikshak et al.,
2013; Willsey et al., 2013). Each of these networks or modules
corresponded to different brain regions along progressing stages
of development. Remarkably, while the groups took different
approaches to develop these networks and assess the potential for
enrichment of candidate ASD risk genes they arrived at similar
results implicating the mid-fetal time periods as a possible critical
window for ASD etiology.
Parikshak and colleagues used BrainSpan RNA-seq data from
human neocortex 8 PCW to 12 months after birth to construct
co-expression modules by Weighted Gene Coexpression
Network Analysis (WGCNA), an unbiased, genomewide method
for constructing networks based on pairwise correlations of
gene expression (Langfelder and Horvath, 2008; Parikshak et al.,
2013).
They identified 17 modules and mapped sets of candidate
ASD risk genes onto proteins within the modules. These gene
sets included: “asdM12” which was derived from a WGCNA
expressionmodule fromASDpatient postmortem cerebral cortex
and “SFARI ASD” which was a subset of 155 genes from the larger
AutDB gene list filtered by gene evidence score (Voineagu et al.,
2011; see Table 3 for detailed gene list descriptions). De novo
variants identified from 2012 whole-exome sequencing studies
performed by O’Roak et al., Sanders et al., and Neale et al. were
also mapped onto networks. They then assessed enrichment for
candidate ASD risk gene within specific co-expression modules,
cortical layers and cell types. The de novo mutation candidate
ASD risk genes were more concentrated in modules designated
M2 (p = 0.006) and M3 (p = 0.0011). M2 peaks at 12–22
PCW andM3 is highly upregulated until PCW 12. The overall set
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TABLE 3 | Referenced Candidate ASD Risk Gene Lists.
Gene list name Compilation method Type Number
of genes
Author, Year
AutDB “PubMed” database search for “gene” + “autism” or “autistic” in the titles and
abstracts. Genes are divided into genetic subcategories and assigned evidence
scores. Licensed to SFARI as SFARI Gene by MindSPec.
Broad 667 Basu et al., 2009
asdM12 Set of genes within a co-expression module (“M12”) highly correlated with ASD
status. Module was constructed using WGCNA on gene expression from ASD
(19) and control (17) postmortem cortex tissue. Samples from Autism Tissue
Bank and Harvard Brain Bank.
Co-expression 88 Voineagu et al., 2011
SFARI ASD Subset of genes from AutDB filtered for gene category syndromic (S) (associated
with syndromes in which a significant percentage of individuals develop autistic
symptoms) and evidence score 1–4 (high confidence—minimal evidence).
Broad 155 Parikshak et al., 2013
Willsey set Genes identified with de novo LoF mutations from whole-exome sequencing
studies (Iossifov et al., 2012; Kong et al., 2012; Neale et al., 2012; O’Roak et al.,
2012a) and an additional 56 quartets from the SSC. Genes are grouped as, high
confident (hcASD) genes (2 or more de novo LoF mutations), or probable (pASD)
genes (one de novo LoF mutation). The genes in the pASD group were estimated
to have a >50% chance of being “true ASD” genes based on TADA analysis.
Simplex dnLoF 131 Willsey et al., 2013
Liu set Genes identified by the DAWN algorithm as being implicated in ASD risk using
data from the PFC-MSC co-expression module developed in Willsey et al. and
from whole-exome sequencing studies in family trios (Iossifov et al., 2012; Kong
et al., 2012; Neale et al., 2012; O’Roak et al., 2012a; Sanders et al., 2012),
quartets (Willsey et al., 2013) and case-controls (ARRA Autism Sequencing
Consortium, De Rubeis et al., 2014)
dnLoF
Rare transmitted
variants
Co-expression
127 Liu et al., 2014
of genes in these modules, including non-ASD risk genes, were
highly enriched for chromatin modifiers, DNA binding proteins,
and transcriptional regulators (p < 1 × 10−4). Modules M2 and
M3 seemed specific to the superficial cortical layers L2–L4 and
cells expressing glutamatergic neurons.
In contrast, the “SFARI ASD” and “asdM12” gene sets
were enriched in modules M13 (SFARI ASD, p = 0.059,
asdM12, p = 3 × 10−15), M16 (SFARI ASD, p = 0.0024,
asdM12, p = 3.5 × 10−15), and M17 (SFARI ASD, p = 0.033,
asdM12, p = 1.0 × 10−7). The overall set of genes in these
modules had a concentration of synaptic proteins (p < 1 ×
10−4) and peaks late in fetal development, starting at 16 PCW
and into birth. An enrichment for fragile-X mental retardation
protein (FMRP) targets was seen in the M2 module, suggesting
a common mechanism between ASD and fragile-X syndrome,
in line with the enrichment of FMRP targets first observed by
Iossifov et al. (2012). On the other hand, 401 genes implicated in
monogenic forms of ID compiled from four publications, showed
little enrichment for any one module suggesting the mid-fetal
time period may be specific to ASD.
Willsey and colleagues took an alternative approach by
focusing on nine high-confidence ASD risk genes, defined as
having two or more LoF mutations, and determining their co-
expression networks (Willsey et al., 2013; Table 3). These nine
genes were used as seeds to generate networks composed of the
top positively correlated genes. Gene expression data was also
derived from BrainSpan, but based on the Affymetrix GeneChip
Human Exon 1.0 ST Array rather than RNA-seq. In addition, all
brain regions were considered and 15 periods of development,
5.7 PCW–82 years were examined. Developmental periods were
condensed into three time windows resulting in 52 networks
based on time and brain region with transcriptional similarity
as determined by hierarchical clustering. To see if additional
candidate ASD risk genes were enriched in these networks, a
list of 122 candidate ASD genes (termed “Willsey set”) with at
least one LoF mutation identified from whole-exome sequencing
studies was generated and mapped onto the networks (Table 3).
Permutation testing of enriched networks was used to correct
for gene size and GC content. They also looked for enrichment
of this gene set within specific cortical layers and cell types.
Immunostaining and in-situ hybridization was performed on
frontal cortex sections to determine protein expression for five
of the high-confidence ASD genes. Similar to Parikshak et al.,
they found enrichment in networks exhibiting peak expression
between 10–19 (p = 0.003) and 13–24 (p = 0.05) PCW (mid-
fetal time period). These networks were specific to the prefrontal
and primary motor-somatosensory cortex, but in contrast to
Parikshak et al., the networks were specific to the deep layers, L5-
6. Immunostaining revealed thatCHD8 and other ASD genes like
SCN2A, DYRK1A, and TBR1 were highly expressed in cortical
projection neurons, particularly glutamatergic cell types.
In summary, both groups found a convergence of candidate
ASD genes with de novo mutations within the mid-fetal stage
of development, 10–24 PCW. The resulting networks appeared
specific for glutamaterigic cortical projection neurons, but
differed in their implication of specific cortical layers. The
cortical projection neurons form synaptic connections early in
development and may then be highly sensitive to changes in gene
regulation (Willsey et al., 2013). Therefore, de novo mutations
in genes like CHD8 may largely impact the midfetal stage of
development particularly prefrontal and motorsensory cortex
development.
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CHD8 DISRUPTION ALTERS MANY
TARGETS INCLUDING OTHER CANDIDATE
ASD RISK GENES
The heterozygous LoF CHD8mutations seen in ASD likely result
in insufficient levels of CHD8 protein and the disregulation of
CHD8 targets. The regulatory landscape and widespread reach of
CHD8 regulation has been examined in three recent studies using
genomic approaches and a number of different neural cellular
models that attempt to mimic early development (Figure 2A).
Sugathan and colleagues performed knockdown of CHD8 in
induced pluripotent stem cell (iPSC) derived neuron progenitor
cells (NPCs) using lentiviral delivery of six independent shRNA
achieving a range of 38–69% reduction in CHD8 mRNA
expression (Sugathan et al., 2014). They then assessed changes
in gene expression using RNA-seq in these knockdown lines
and also performed chromatin immunoprecipitation-sequencing
(ChIP-seq) in control NPCs to identify CHD8 binding sites.
By contrast, Cotney and colleagues performed ChIP-seq to
locate CHD8 binding sites (under non-perturbed conditions)
in three different systems: human midfetal cortical tissue 16–
19 PCW, H9 derived human neural stem cells (hNSCs), and
embryonic mouse cortex (Cotney et al., 2015). Using primary
tissue allowed for representation of mid-fetal stages critical in
CHD8-ASD development and to evaluate potential differences
between CHD8 binding sites identified in in vivo tissue and
in vitro cells. They also performed CHD8 knockdown in
hNSCs using two lentiviral shRNA, followed with RNA-seq, to
assess changes in gene expression. Finally in the third study,
Wilkinson and colleagues performed knockdown of CHD8,
achieving about a 50% reduction, using siRNA in human SK-
N-SH neural progenitor cells followed by RNA-seq (Wilkinson
et al., 2015). These studies reveal a complex role for CHD8
in ASD development as it appears to regulate expression of
additional candidate ASD risk genes by both indirect and direct
means.
Sugathan and colleagues found that knockdown of CHD8
lead to differential expression of some 1756 genes (at nominal
P < 0.05; 369 genes at q < 0.05 Benhamini-Hochberg), most of
which were upregulated (n = 1140, p < 0.05; 286, q < 0.05;
Sugathan et al., 2014). The set of down regulated genes (n = 616)
were enriched for roles in neuronal development. Intriguingly,
this same set of downregulated genes was also enriched for
candidate ASD risk genes from a large set of 628 genes from
AutDB (p = 3.25 × 10−8; Table 3). Though no enrichment
for any candidate ASD risk gene sets were observed in the set
of up-regulated genes, cancer associated genes, defined by The
Cancer GenomeAtlas, were enriched in this group. Loss ofCHD8
function has been observed in a broad range of tumor types
and other chromatin regulators have been implicated in cancer
development (Lawrence et al., 2014). This suggests CHD8 may
have other important roles extending past development and may
be a point of commonality between some cancers and ASD.
In the ChIP-seq data, 7324 reproducible binding sites were
identified (Benjamini-Hochberg q < 0.05). CHD8 preferentially
bound to regions that in ES cell-derived neuroprogenitor lines
from the Roadmap Epigenomics are marked with histone H3
trimethyl Lysine4 (H3K4me3), an indicator of active TSSs
(Bernstein et al., 2010). These TSSs were strongly enriched in
the CHD8 set, 83%, relative to the genome background, 1%. A
small number of binding sites, 4%, overlap enhancer marked
sites (H3K4me1), representing a two-fold enrichment. Sequence
motifs at CHD8 binding sites were enriched for CTCF and YY1
transcription factor motifs. Genes with CHD8 sites were enriched
for p53, hedgehog, and cell cycle pathways.
Combining the differentially expressed (DE) set of genes with
CHD8 binding data, Sugathan and colleagues further explored
a number of enrichments using functional classifications,
candidate ASD risk gene sets, and other disease gene sets.
Overall, only 9.2% of genes with CHD8 binding sites were
DE in the nominal P gene set (29.7% of all the DE genes).
Candidate ASD risk genes from AutDB were enriched in the set
of nominally downregulated genes, but not targeted by CHD8
(p = 1.09 × 10−9). This set of candidate ASD risk genes was
enriched for pathways involved in neurodevelopment such as
axon guidance and neurotransmitter regulation. Enrichment of
the more restricted set of AutDB genes from Parikshak et al.,
“SFARI ASD” was also observed in the downregulated, non-
CHD8 bound genes (p = 2.26 × 10−2). However, genes from
Willsey et al., “Willsey set” were enriched as CHD8 bound
genes (p = 4.34 × 10−3), but were not associated with any
changes in gene expression. CHD8 bound genes in the “Willsey
set” were enriched for chromatin and transcription. Though
these data sets are not independent, they do have different gene
representations, with the “Willsey set” more biased toward rare
de novo variants. CHD8 binding sites with or without differential
expression were explored in the modules described in Parikshak
et al. The downregulated genes with no CHD8 binding site were
enriched in modules M13, M16, and M17 which correspond
to mid-late fetal develop whereas CHD8 bound genes were
enriched in modules M2 andM3 corresponding to early-midfetal
development. CHD8 bound genes were also highly enriched
in TGCA cancer associated genes and also showed no specific
enrichment in either up or downregulated genes. No other
disease gene sets from the 184 lists for complex disease and traits
available from the National Human Genome Research Institute
were as significantly enriched as the ASD or cancer gene sets for
CHD8 targets or genes affected by CHD8 knockdown. These data
suggest both direct and indirect roles of CHD8 in gene regulation,
particularly in the development of ASD and cancer.
Cotney et al. found 9414 reproducible CHD8 binding sites
in hNSCs and 4428 in human midfetal brain. Between these
two human sets, 2777 sites were overlapping. Chromatin state of
hNSC CHD8 binding sites was determined from data generated
on hNSCs from their own lab and the ENCODE/Roadmap
Epigenomics (Bernstein et al., 2010). Similarly to Sugathan and
colleagues, they found that CHD8 had strong affinity for TSSs
labeled with H3K4me3 or H3K27ac and 99% of promoters bound
by CHD8, 8056, were active (Cotney et al., 2015). Additionally,
they observed that a small fraction of CHD8 binding sites, 1028,
were indicative of enhancer functions. Moreover, CHD8 binding
negatively correlated with H3K27me3, indicative of repression.
Enriched sequence motifs for transcription factors included
CTCF, E2F, YY1, and Sp/Kruppel-like family.
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FIGURE 2 | CHD8 functional genomics studies. (A) Flow chart describing functional genomics studies, Sugathan et al., Cotney et al., and Wilkinson et al.
including CHD8 knockdown in cellular models of early neural development and ChIP-seq. Cotney et al. also incorporated primary fetal human cortical and embryonic
mouse brain tissue into the ChIP-seq analysis. Integrating the gene expression and CHD8 binding profiles, networks of CHD8 regulated genes were constructed and
analyzed for enrichment of candidate ASD risk genes. (B) CHD8 targeted candidate ASD risk genes found in the “Willsey set” observed between studies. Genes
found in Cotney et al. specifically have CHD8 bound promoters. Human sites in Cotney et al. are shared between hNSCs and brain tissue. Though not included as
part of the “Willsey set” in Cotney et al., POGZ is included here. POGZ was noted as having a CHD8 bound promoter and it is one of the high confidence “Willsey set”
genes. (C) List of the shared candidate ASD risk genes from the “Willsey Set” bound by CHD8 between both studies and conserved between human and mouse.
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Genes that had CHD8 binding sites identified in both midfetal
brain and hNSCs were highly enriched for candidate ASD risk
genes from two gene sets as defined by and Liu et al., “Liu
set” (p < 0.0001) and the “Willsey set” (p < 0.0001; Willsey
et al., 2013; Liu et al., 2014), while genes with binding sites
only in hNSCs were not enriched. Candidate ASD risk genes
with CHD8 binding sites were enriched for chromatin regulation
and modification. CHD8 targets supported by both human
datasets were largely evolutionarily conserved. Among mouse
(E17.5 cortex), human midfetal brain, and hNSC, 1910 CHD8
binding sites were shared and also enriched for candidate ASD
risk genes from both aforementioned gene sets (p < 0.0001),
further suggesting a conserved mechanism for CHD8 regulation
in development. Of the candidate ASD risk genes from the
“Willsey set” found to contain CHD8 binding sites, 25 were
shared between Cotney et al. and Sugathan et al. and were
also conserved in mouse (Figures 2B,C). Enrichment of CHD8
bound proteins was also observed in networks reconstructed
from the Willsey et al. 10–19 and 13–24 PCW networks using
genes with active promoters (Willsey et al., 2013).
In their knockdown of CHD8 in hNSC, genes with conserved
CHD8 binding sites had the greatest fraction of DE genes (56%)
as compared to genes with binding sites only found in hNSC
(46%) or hNSC and human brain (54%). Cell cycle, Hippo,
and p53 pathways were among the pathways most affected.
Candidate ASD risk genes actually exhibited the most significant
dysregulation compared to any other set of CHD8 targeted genes
(∼60% for both gene sets). Additionally, those candidate ASD
risk genes most DE, tended to be downregulated.While Sugathan
et al. did find that candidate ASD risk genes from the Willsey
set were enriched as CHD8 targets, they were not significantly
DE in either direction. In contrast, Cotney et al.’s data suggest
that CHD8 directly activates this same set of candidate ASD risk
genes.
In line with the other studies, Wilkinson et al. found
CHD8 reduction had a global impact on gene expression.
Interestingly, the top DE genes in this study were noncoding
RNAs, the majority of which were upregulated. Noncoding
RNAs have only recently been appreciated as having a potential
role in neurodevelopment and may be yet another layer in
transcriptional control. Enrichment of candidate ASD risk genes
Parikshak et al. “SFARI ASD” was only seen in the set of
downregulated genes, similar to Cotney et al. as were processes
involved in regulation of neuron projection, differentiation
and neurogenesis (Parikshak et al., 2013; Wilkinson et al.,
2015).
In summation, CHD8 appears to act as a master regulator in
the foundational pathways of the developing brain, particularly
those that may also be implicated in ASD development.
Yet the mechanism for regulation remains unclear. Many
of the candidate ASD risk genes are direct targets of
CHD8 protein and are also involved in chromatin regulation
(Figure 3A). Cotney et al. and Wilkinson et al. indicate
that CHD8 directly activates expression of these genes but
Sugathan et al. suggest that the presence or absence of
CHD8 may not influence expression, despite the genes having
a binding site. Other candidate ASD risk genes lack a
CHD8 binding site, but still appear to be affected by CHD8
expression indicating an indirect mechanism of regulation.
How CHD8 may be able to influence gene activation or
transcription factor activity without directly binding to DNA
is not clear, but may involve binding to other co-regulators
or chromatin marks (Figure 3B). Continued study will be
needed to fully elucidate the mechanism for CHD8 regulation
in ASD.
CONCLUSIONS AND FUTURE
DIRECTIONS
From exome sequencing studies, a number of high-confident
ASD risk genes have been identified with CHD8 emerging as
particularly strong. Both human case studies and animal models
suggest a common phenotype for CHD8 mutation including
a significant association with ASD diagnosis and behavior,
macrocephaly, and dysfunction in the enteric nervous system.
ThoughASD is highly heterogeneous,CHD8 systems biology and
functional genomics studies give some hint as to the complex
nature of the disorder. The CHD8 protein and those of many of
the other candidate genes serve as master regulators, influencing
the expression of a large network of genes and pathways that
control neuron formation, proliferation, and differentiation. The
timing of proper neural development is a highly regulated
phenomenon, requiring a concerted effort by many different
genes. While it’s clear that CHD8 controls expression of genes
involved in these developmental processes, the manner in
which CHD8 regulates them is still unclear. Initial studies
suggest that CHD8 may act as a direct repressor by modifying
chromatin tomake it less accessible. However, the loss of function
studies point toward a role for CHD8 as an activator in the
emerging ASD gene network. One of the consistent findings
from these and previous studies is that CHD8 is associated
with actively transcribed genes and has affinity for H3K4me3
labeled promoters suggesting an influential role in global gene
expression. CHD8 may function to make promoters more
accessible through chromatin remodeling, promote transcription
factor binding, or indirectly enhance expression through as of
yet, unknown mechanisms that may involve interactions with
H3K4me3 itself. The mechanism of CHD8 regulation is likely to
be gene dependent as well.
It’s also still uncertain which CHD8 targets may be relevant
for ASD. Though the studies indicate a number of candidate
ASD risk genes contain CHD8 binding sites, further functional
studies will be required to demonstrate if these genes interact
in a physiologic setting. Additionally, although enrichment for
candidate ASD risk genes may be seen in specific neuron
types, it is still unclear how the alterations in these neurons
ultimately relate to behavioral phenotypes. It will be important
to determine how CHD8 affects neural circuitry and connect
these affects to autistic associated behaviors. Lastly, development
of co-expression modules have proved useful in identifying
relevant ASD developmental time periods and interactions
between candidate ASD risk genes, including CHD8. However,
developing methods that integrate multiple types of data such
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FIGURE 3 | Proposed mechanisms for CHD8 transcriptional activation. (A) CHD8 is most commonly found near active transcription start sites with histone
modifications H3K4me3 (green circle) or H3K27ac (yellow circle). CHD8 may directly activate genes by directly binding near the transcriptional start site and promote
transcription factor activity or recruitment. (B) CHD8 may indirectly activate genes through interactions between modified histone sites and other co-regulators to
make chromatin more assessable.
as co-expression and protein-protein interactions may improve
identification of ASD and other neurodevelopmental disorder
specific networks, as proposed recently (Hormozdiari et al.,
2015). Through the combination of rapidly advancing genetics
and the development of relevant neural models, ASD biology
is slowly beginning to resolve, and providing the potential for
individualized approaches to therapy.
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